Prof. Michael Welsh |Genetics and Molecular Biology | Best Researcher Award
Uppsala University, Sweden
Professor J. Michael Welsh is an internationally recognized biomedical scientist renowned for his pioneering research in the field of medical cell biology, particularly focusing on cystic fibrosis, epithelial ion transport, and pulmonary disease mechanisms. As a leading figure in translational medicine, Professor Welsh has made groundbreaking discoveries that have reshaped the global understanding of cystic fibrosis pathophysiology, contributing directly to the development of therapeutic strategies that have improved patient outcomes worldwide. His research has centered on the molecular and cellular basis of epithelial ion channel dysfunction, elucidating the mechanisms by which CFTR gene mutations cause abnormal chloride transport and disrupted mucociliary clearance in the airways. Throughout his distinguished career, Professor Welsh has authored over 610 peer-reviewed publications, accumulating more than 62,725 citations and achieving an h-index exceeding 130, underscoring his far-reaching influence in the biomedical community. His scholarly excellence and innovation have earned him election to the U.S. National Academy of Sciences and the National Academy of Medicine, reflecting his standing as one of the foremost authorities in molecular physiology and genetics. In addition to his scientific achievements, Professor Welsh has demonstrated exemplary leadership as the founder of the University of Iowa Cystic Fibrosis Research Center, fostering cross-disciplinary collaborations with clinicians, geneticists, and pharmaceutical scientists to accelerate the translation of basic research into clinical applications. Professor Welsh’s research has profoundly influenced not only molecular medicine but also public health, by shaping therapeutic approaches that extend life expectancy and quality of life for individuals affected by genetic and respiratory diseases. His mentorship of emerging scientists and his commitment to collaborative, patient-centered innovation exemplify his enduring contribution to science and society. Through his visionary work, Professor Welsh continues to bridge the gap between molecular discovery and clinical transformation, embodying the essence of global scientific excellence and impact.
Profiles: Scopus | ORCID
Featured Publications
-
Celis, N., Miller, D. P., Tarara, T. E., Weers, J. G., Thornell, I. M., Welsh, M. J., & Burke, M. D. (2025). Molecular prosthetics and CFTR modulators additively increase secretory HCO3− flux in cystic fibrosis airway epithelia. bioRxiv.
-
Welsh, M. J. (2025, September 11). Rewriting the chapter on cystic fibrosis. JAMA.
-
Welsh, M. J. (2025, August 10). A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. Journal of Parkinson’s Diseases.
-
Thornell, I. M., Lei, L., McCray, P. B. Jr., & Welsh, M. J. (2025). Do pulmonary ionocytes absorb chloride or secrete chloride? American Journal of Physiology-Cell Physiology.
-
Karp, P., Welsh, M., Kim, B. R., Keen, H., Rauckhorst, A. J., Taylor, E. B., Chimenti, M. S., & Rehman, T. (2025, January 24). The oxygen level in air directs airway epithelial cell differentiation by controlling mitochondrial citrate export. Science Advances.
Professor Michael Welsh’s work has revolutionized the understanding and treatment of cystic fibrosis by uncovering the molecular mechanisms of CFTR dysfunction, leading to life-changing therapies for patients worldwide. His groundbreaking research bridges molecular biology and clinical medicine, driving global innovation in genetic disease treatment and advancing precision healthcare.